by Keith Koehler, President of Excite Pharma
Excite Pharma has entered 2025 with groundbreaking momentum, and I couldn’t be more thrilled to share this announcement with our partners, colleagues, and stakeholders. On January 23, 2025, the Kansas Board of Pharmacy officially granted Excite Pharma our outsourcing facility license under the 503B designation. This approval not only marks a significant milestone for our company but also paves the way for us to better serve our customers and improve patient care nationwide.
What the 503B License Means for Excite Pharma
This new 503B outsourcing license allows Excite Pharma to manufacture and distribute sterile products at our facility in Tonganoxie, Kansas. While we’ve been federally licensed and trusted for over 15 years as a leading CDMO (Contract Development and Manufacturing Organization), this license empowers us to take on a new role in addressing critical supply shortages and providing high-quality products directly to pharmacies, doctors, and healthcare systems.
Our 503B capabilities open the door to producing larger-scale batches of sterile injectable drugs—specifically targeting products on the FDA’s shortage list—to meet the needs of hospitals, 503A compounding pharmacies, and other critical care providers. Excite Pharma can manufacture thousands of units in a single batch, ensuring more patients get access to the medications they need without delay.
A Natural Next Step for Excite Pharma
Founded in 2009, Excite Pharma has always been focused on innovation and patient safety. Over the last 15 years, we’ve established ourselves as a trusted partner in the development and manufacturing of new chemical entities, aseptic vials, nasal gel products, and spray technologies. With this 503B license, we can now bring the same meticulous quality standards to producing and distributing critical medications on a much larger scale.
It’s worth highlighting that our manufacturing sweet spot lies in “small batch” production. Our facilities are optimized to produce batch sizes ranging from 5,000 to 10,000 units, which perfectly aligns with the needs of hospital networks, veterans’ healthcare systems, and pharmacies looking for reliable supply chain solutions. These capabilities ensure we are perfectly situated to meet urgent demands while maintaining our commitment to quality and compliance.
Addressing a Critical Market Need
This expansion is not just about growth for Excite Pharma; it’s about making a difference in the healthcare industry. Drug shortages remain a significant challenge, and our ability to compound and supply larger volumes of products—including injectables and controlled substances—has the potential to alleviate pressure on healthcare systems nationwide.
One particularly exciting opportunity is partnering with 503A facilities. By leveraging our 503B status, we can provide these pharmacies with ready-to-use products, allowing them to focus on other specialized formulations. This collaboration creates a win-win scenario that improves efficiency and expands patient access to essential medications.
Building for the Future
The approval of our 503B license caps off a period of significant investment in our facilities and team. Over the past year, we’ve expanded our workforce, bringing on world-class scientists, QA experts, and manufacturing professionals who are aligned with our mission of improving lives through innovative pharmaceutical solutions. The quality of our team—combined with our state-of-the-art facilities in Kansas—positions us for an incredible 2025 and beyond.
A Call to Action: Join Us in Making an Impact
As we gear up to begin production under our new license, we’re inviting 503A pharmacies, hospital networks, and other potential partners to connect with us today. Given the initial setup time required to launch new production lines, now is the perfect time to get in line. If you’re in need of a batch ranging from 5,000 to 10,000 units and are looking to have productlater this year, I urge you to contact us immediately.
We’re proud to say that orders are now open, and the demand for our services is already high. By acting now, you’ll secure your place in our queue and ensure timely delivery of your needed products.
Looking Ahead to 2025 and Beyond
At Excite Pharma, we’re motivated by the opportunity to make a tangible difference in patient outcomes. Our journey as a newly licensed 503B facility is just beginning, but we’re already envisioning the impact we can make on the healthcare landscape in 2025. This milestone is a testament to our dedication to quality, innovation, and the communities we serve. Thank you to everyone who has supported us along the way—the best is yet to come.
Let’s make 2025 an extraordinary year together.
~ Keith Koehler
President, Excite Pharma
